

**REMARKS**

Upon entry of the present amendment, claims 32 and 93-106 are pending. The amendment to claim 32 and claims 93-96 is made simply to make clear that the derivative can be a derivative of insulin or of an insulin analogue and finds support at page 7, lines 4-6 and lines 18-22. Added claims 97-106 find support inter alia at page 7, lines 16 and 23-24 of the specification and in the Examples (see page 22, line 10).

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested.

The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: May 6, 2008

/Richard W. Bork, Reg. No. 36,459/

Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Inc.  
Customer Number 23650  
(609) 987-5800

Use the following customer number for all correspondence regarding this application

**23650**

PATENT TRADEMARK OFFICE